A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aims of the trial are to assess the safety and the efficacy of SPM 962 following once-a-daily transdermal administration within a range of 2.25 to 6.75 mg/day in Japanese patients with restless legs syndrome (RLS) in a multi-center, open-label trial. The maximum treatment period is 53 weeks. The trial is an extension trial from the precedent 6-week, double-blind, randomized, placebo-controlled, parallel-group comparative trial(243-07-003). The trial is also for an exploratory investigation of incidence of augmentation, the most problematic complications in dopaminergic treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.
• Treatments: N 0437; Rotigotine

Criteria

Inclusion Criteria:

• Subject completed the preceding trial 243-07-003 (NCT00666965)

Exclusion Criteria:

• Subject discontinued from the preceding trial 243-07-003 (NCT00666965)

• Subject had a serious adverse event which association with the investigational drug is not ruled out during trial 243-07-003

• Subject had a persistent serious adverse event at the baseline, which was observed and association with the investigational drug is ruled out during trial 243-07-003.

• Subject had persistent hallucination or delusion during trial 243-07-003.

• Subject had psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline.

• Subject had orthostatic hypotension or a systolic blood pressure (SBP) ≤ 100 mmHg and had a decrease of SBP from spine to standing position ≥ 30 mmHg at baseline.

• Subject had a history of epilepsy, convulsion etc. during trial 243-07-003.

• Subject developed serious ECG abnormality at the baseline.

• Subject had QTc-interval ≥ 500 msec at the baseline or subject had an increase of QTc-interval ≥ 60 msec from the baseline in the trial 243-07-003 and had a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.

• Subject had a serum potassium level < 3.5 mEq/L at the end of the taper period in trial 243-07-003.

• Subject had a total bilirubin ≥ 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or ≥ 100 IU/L) at the end of the period in trial 243-07-003.

• Subject had BUN ≥ 30 mg/dL or serum creatinine ≥ 2.0 mg/dl at the end of the taper period in trial 243-07-003.

• Subject who planned pregnancy during the trial.

• Subject was judged to be inappropriate for this trial by the investigator for the reasons other than above.